Why there is no GP referral and what that means for you

No referral from your GP is needed to access Liquid Cartilage™ (ChondroFiller™) at Lincolnshire Hip — you can make contact directly, without first working through an NHS pathway.

That distinction matters, because the standard NHS hip route does not include injectable collagen scaffolds at any stage. The typical NHS journey runs from GP appointment through MSK triage, supervised physiotherapy, and corticosteroid injections, with eventual hip replacement as the surgical endpoint. Regenerative scaffold treatments fall entirely outside this sequence. As of mid-2026, NICE has issued no health technology appraisal approving ChondroFiller™ for routine commissioning, and the Lincolnshire Integrated Care Board does not fund it. There is no Individual Funding Request pathway that reliably covers it either.

This is a commissioning timeline issue, not a clinical verdict. ChondroFiller™ is a CE-marked Class III medical device — the same regulatory tier as hip implants — and the gap between CE-marking and formal NICE evaluation is a structural feature of how novel devices enter the NHS, not an indication that the technology has been found wanting. The same lag applied to other now-established treatments during their own evidence-accumulation periods.

Because the treatment sits entirely in the private sector, self-funding is the realistic route for almost all patients in Lincolnshire. Major insurers including Bupa and AXA do not routinely cover collagen scaffold injections, so pre-authorisation with any insurer is worth confirming before booking. Lincolnshire Hip, part of the MSK Doctors group, accepts patients without referral for hip assessment — and there is no requirement to have exhausted NHS options before being seen.

The three entry points into the Lincolnshire Hip pathway

The Lincolnshire Hip booking page is structured as a three-stage funnel, each option calibrated to a different level of readiness.

The free 2-minute readiness check is a digital self-assessment — no human contact, no appointment required. It works through a structured set of questions about symptoms, goals, and history, then signals whether a patient's profile sits closer to a non-surgical pathway (such as Liquid Cartilage™ or Arthrosamid) or a surgical one. For anyone still orienting themselves, this is the natural starting point.

The free 15-minute discovery call suits patients who have done some initial research and want a brief conversation to test whether Liquid Cartilage™ is likely to apply to their situation — before committing to a paid appointment. Nothing is charged and there is no obligation to go further.

The £250 private consultation with Professor Paul Lee is the clinical assessment stage. Imaging — X-ray, MRI, or both — is reviewed alongside a full symptom history, and candidacy for each treatment option is discussed in detail. Patients who already hold recent imaging are welcome to bring it.

For those who have separately reached a decision about joint replacement rather than injection treatment, a £1,000 deposit secures a date on the SPAIRE hip replacement pathway — a distinct route that runs parallel to the injection track, not through it.

All three injection-pathway entry points are available at Lincolnshire Hip's Grantham and Sleaford clinics. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

Self-assessing whether Liquid Cartilage™ suits your hip

Candidacy for Liquid Cartilage™ at the hip rests on three overlapping factors: the pattern of cartilage damage visible on imaging, the degree of joint-space preservation, and the overall picture of symptoms and activity.

The target presentation is focal or diffuse hip cartilage damage graded at III or IV on clinical grading scales — meaning the affected surface has worn through to an advanced degree, but the joint as a whole may still have meaningful space between the bones. That is the zone between early wear and end-stage collapse. Grade III–IV damage is confirmed through MRI and/or X-ray at the consultation stage; a patient who brings existing imaging to the £250 appointment with Professor Paul Lee can often streamline this step.

Bone-on-bone status does not automatically rule out the injection pathway, and there is no published age ceiling for the injection route. What matters is the overall joint picture — how much usable space remains, how concentrated the damage is, and what the patient realistically wants from treatment. Where significant joint-space loss has already occurred, the consultation may redirect toward a different option.

Liquid Cartilage™ (ChondroFiller™) and Arthrosamid serve different purposes and should not be conflated. ChondroFiller is a regenerative collagen scaffold that supports the body's own repair processes; Arthrosamid is a non-regenerative hydrogel designed to reduce symptom burden through cushioning rather than tissue repair. Some patients are candidates for one, some for both, and some for neither — the consultation determines which applies.

No randomised controlled trial specifically examining ChondroFiller in the hip joint has been published to date. The evidence base draws on CE-marking data, cohort studies, and clinical adoption experience, including published outcomes suggesting meaningful improvements in hip function scores. That limitation is worth knowing before the appointment rather than after.

What the consultation with Professor Paul Lee involves

Arriving at the £250 appointment, the first priority is context — not imaging. Professor Paul Lee takes a structured clinical history covering the pattern, onset, and behaviour of hip symptoms alongside any relevant comorbidities, previous treatments, and activity goals. This shapes how the imaging review that follows is interpreted.

If you have existing X-ray or MRI results, bring them. Professor Paul Lee will review the defect pattern, degree of joint-space preservation, and any structural features that influence candidacy. Where existing imaging is inconclusive or out of date, further scans — including open MRI available at both Grantham and Sleaford — may be arranged before a final recommendation is made. The appointment is not held up waiting for perfect images if enough information exists to begin.

The clinical discussion covers the realistic options given the joint picture: Liquid Cartilage™ (ChondroFiller™), Arthrosamid, PRP, or a different pathway entirely if the imaging warrants it. For patients being considered for Liquid Cartilage™, the collagen scaffold mechanism, recovery timeline, and the approximately four-to-six-week protected loading period are all explained before any decision is reached. Combination treatment rationale — where more than one modality may be appropriate — is addressed at the same stage.

The outcome of the appointment is a clinical recommendation. Some patients leave with a clear treatment plan; others require a follow-up scan first. Neither Grantham nor Sleaford requires travel to London — both sites run full consultation and injection services.

The injection appointment: procedure, recovery, and protected loading

On the day of the injection, the appointment is structured as a routine outpatient visit — no theatre, no hospital admission, no overnight stay. Patients arrive at either the Grantham or Sleaford clinic and are prepared using local anaesthetic only; no general anaesthesia is involved.

Once the anaesthetic has taken effect, the ChondroFiller collagen scaffold is placed into the hip joint under live ultrasound imaging guidance. Real-time ultrasound visualisation allows precise, image-guided delivery of the scaffold to the affected area of the joint — a straightforward outpatient injection without incisions or surgical entry. The scaffold self-gels within minutes inside the joint, bonding to surrounding tissue and forming a stable three-dimensional matrix. From that point, the biological integration process begins.

Recovery and protected loading

Patients leave the clinic on the same day but the four-to-six weeks that follow require a degree of considered activity management. High-impact movement — running, heavy lifting, sustained standing — should be avoided during this window to allow the collagen matrix to integrate with the surrounding joint tissue. Low-load walking and routine daily movement are generally manageable within the protected period; the aim is reduced stress on the joint rather than full rest.

Planning around this timeline before the appointment makes the recovery easier to accommodate. Patients who factor the protected loading window into work schedules and upcoming commitments in advance tend to find the period more straightforward to manage. A consultant assessment at the £250 appointment stage is the appropriate point to confirm what the protected period will mean for individual circumstances.

Cost and insurance: what to expect financially

The Liquid Cartilage™ injection at Lincolnshire Hip is priced at £2,995 — toward the lower end of the UK-wide range for ChondroFiller, which runs from approximately £3,000 to £9,800 depending on clinic and case complexity. The £250 private consultation with Professor Paul Lee is billed separately; the online readiness check and 15-minute discovery call carry no fee.

The outpatient injection pathway attracts no additional facility or anaesthetic charges — local anaesthetic is used, and no theatre admission or overnight stay is involved.

As of mid-2026, NICE has not approved ChondroFiller for routine NHS commissioning. Because the treatment sits outside any Integrated Care Board funding framework, private medical insurers — including Bupa and AXA — do not routinely authorise it. The commissioning gap reflects the evidence-accumulation timeline common to Class III medical devices, not a clinical rejection of the treatment; self-funding is the realistic expectation for almost all patients at present.

Where a combination approach is recommended at consultation — ChondroFiller alongside PRP, for instance, priced at £1,200 at Lincolnshire Hip, or Arthrosamid at the same £2,995 rate — the combined cost should be confirmed before committing. The consultation stage is the right point to establish what any multi-modality plan would involve financially.